China
Africa
Explore chapters and articles related to this topic
Drug profiles: generic names A-Z
Published in Jerome Z. Litt, Neil H. Shear, Litt's Drug Eruption & Reaction Manual, 2017
Clinically important, potentially hazardous interactions with: carbamazepine, dexamethasone, dexlansoprazole, esomeprazole, lansoprazole, omeprazole, oxcarbazepine, pantoprazole, phenobarbital, phenytoin, rabeprazole, rifampin, rifapentine, St John’s wort
Improving clinical outcomes of Barrett’s esophagus with high dose proton pump inhibitors and cryoablation
Published in Annals of Medicine, 2023
Patients continued PPI-BID for at least one year, and indefinitely if dysplasia had been found initially. For patients with only NDBE (IM) initially, PPI-BID was tapered after one year to once daily, usually dexlansoprazole 60 mg if possible. To assess symptoms, medication regimens, compliance, adverse events, side effects, requirements for surgery, scheduling of endoscopy, and review of the importance of reflux control with PPI-BID for successful outcomes, patients were scheduled for follow-up usually in person or if appropriate by telephone at least every three months until CE. Then, for the next 3 years after CE, follow-up was scheduled depending on clinical course every 3–6 months if they had initial dysplasia or significant symptoms, or every 6–12 months if they had initial NDBE or were asymptomatic. Compliance status with PPI regimen was defined as: (1) compliant – BID-PPI or dexlansoprazole daily taken at least 90% of time; (2) daily compliant – PPI taken at least 90% of time; (3) partially compliant – < 4 PPI doses/week (PRN) for ≤6 months; and (4) noncompliant – no or PRN PPI for > 6 months.
Proton pump inhibitors and increased reporting odds of renal neoplasms: FAERS-based adverse event data mining and analysis
Published in Expert Opinion on Drug Safety, 2022
Weijuan Song, Lei Shi, Yanhong Wang, Zisen Zhang
In this study, positive signals of neoplasms only occurred in renal neoplasms and gastrointestinal neoplasms. PPIs are mainly used for the treatment of gastric and esophageal acid-related diseases, which are themselves associated with a high risk of gastric neoplasms, therefore it cannot be considered that there is a causal relationship between the use of PPIs and the occurrence of gastric neoplasms. The use of PPIs showed higher risk in renal neoplasms, and the risk of RCC was still higher even when confounders were controlled. Pantoprazole and dexlansoprazole did not significantly raise the risk of renal cysts or RCC, while lansoprazole was of the greatest risk. Although current evidence is insufficient to establish a causal relationship between PPIs and RCC, considering the wide and potential long-term use of PPIs, for example, long-term use of NSAIDs with gastrointestinal symptoms or Barrett’s esophagus, the association between PPIs and renal neoplasms is noteworthy.
An update on the latest chemical therapies for reflux esophagitis in children
Published in Expert Opinion on Pharmacotherapy, 2019
Marc Bardou, Kyle J. Fortinsky, Nicolas Chapelle, Maxime Luu, Alan Barkun
PPIs, include omeprazole, esomeprazole, pantoprazole, and lansoprazole, and is some countries dexlansoprazole. These medications irreversibly bind to the hydrogen-potassium ATPase pump residing on parietal cell membranes thereby blocking acid secretion. PPIs also have a longer duration of action and are less likely to develop tolerance over time when compared to H2RAs which tend to develop tachyphylaxis within a few weeks with repeat dosing [21]. Although there are several different PPI drugs that have similar efficacy and tolerability, omeprazole, esomeprazole, and lansoprazole have been the most widely studied in children, although pantoprazole can also be used. The latest in the class, dexlansoprazole, has been assessed in adolescent with NERD, in a non-comparative manner [22]. PPI is not approved for children below 1 year of age and 10 kg of body weight.